Jordan S. Orange, MD, PHD

Pediatric Allergy and Immunology
Allergy and Immunology, Pediatrics
More specialties
Accepting New Patients
Treats Children
Profile Headshot

Overview

Jordan Scott Orange, MD, PhD, chair of pediatrics at Columbia University College of Physicians and Surgeons and physician-in-chief of NewYork-Presbyterian/Morgan Stanley Children’s Hospital, comes to Columbia from Baylor College of Medicine, where he was vice chair for research in Pediatrics, director of the Pediatrician-Scientist Training and Development Program, and chief of immunology, allergy, and rheumatology. At Texas Children's Hospital Dr. Orange held the Louis and Marybeth Pawleek Endowed Chair, and was director of the Jeffrey Modell Diagnostic and Research Center for Primary Immunodeficiency and of the Center for Human Immunobiology.

An international leader in pediatric primary immunodeficiency and the immunobiology of human natural killer cells, in his research Dr. Orange combines novel disease discovery with basic cell research to translate underlying biological mechanisms of disease into clinical applications. His research has been continuously funded by the National Institutes of Health and he has published over 250 papers. Dr. Orange is a member of the American Society for Clinical Investigation and the American Pediatric Society and was a recipient of the E. Mead Johnson Award for research accomplishment in pediatrics from the Society for Pediatric Research.

Dr. Orange received his AB, PhD, and MD degrees from Brown University, and went on to residency training at Children's Hospital of Philadelphia, clinical fellowship at Boston Children's Hospital, and a post-doctoral research fellowship at Harvard. He served for nearly 10 years on the faculty of the University of Pennsylvania School of Medicine before moving to Houston in 2012.

 

Areas of Expertise / Conditions Treated

  • Immunodeficiencies Treatments
  • Immunodeficiency Disorder
  • Pediatric Immunology
  • Severe Combined Immunodeficiency (SCID)

Academic Appointments

  • Reuben S. Carpentier Professor of Pediatrics

Administrative Titles

  • Chair, Department of Pediatrics

Hospital Affiliations

  • NewYork-Presbyterian / Columbia University Irving Medical Center
  • NewYork-Presbyterian Morgan Stanley Children's Hospital

Gender

  • Male

Schedule an Appointment

Phone Appointments

New and Existing Patients:

Connect Patient Portal

For existing patients, login to make an appointment, view documentation or contact your care provider.

Connect Sign In

Credentials & Experience

Education & Training

  • MD, 1997 Brown Univeristy
  • Internship: 1998 Children's Hospital - Philadelphia
  • Residency: 2000 Children's Hospital - Philadelphia
  • Fellowship: 2003 Boston Children's Hospital

Committees, Societies, Councils

National Societies (and leadership roles):

American Academy of Allergy, Asthma and Immunology

Clinical Immunology Society

American College of Allergy Asthma and Immunology

American Association of Immunologists (Member)

American Academy of Pediatrics (Fellow)

Society for Natural Immunity (Member)

Society for Pediatric Research (Elected Member)

Pan-American Group for Immunodeficiencies (Member)

Robert A. Good Immunological Society (Elected Member)

American Society for Clinical Investigation (Elected Member)

Henry Kunkel Society (Elected Member)

American Society for Cell Biology (Member)

ASCB Ambassador for Baylor College of Medicine 2017

American Pediatric Society (Elected Member)

American Academy of Pediatrics Section on Allergy and Immunology- Executive Council Member 2016-2019

Board Certifications

  • Allergy and Immunology
  • Pediatrics

Honors & Awards

2018 The Academy of Medicine, Engineering, and Science of Texas – Edith and Peter O’Donell Award for outstanding achievement in medical research

2017 Society for Pediatric Research – E. Mead Johnson Award for research achievement in Pediatrics

2017 Baylor College of Medicine – Michael E DeBakey Award for Research Excellence

2017 Houstonia Magazine – Houston’s top doctors, Allergy and Immunology

2016 American Pediatric Society - Norman J. Siegel New Member Outstanding Science Award

2016 American Pediatric Society – Elected Member

2016 Texas Children’s Hospital “Superstar Physician”

2016 2017 Houston Chronicle – Top Doctors

2015 Lee Howley Sr. Prize for Team Science (for discovery of COPA syndrome) Arthritis Foundation

2014 “H” Texas Magazine – Houston’s Top Docs (Allergy and Immunology)

2013 Henry Kunkel Society – Elected Member

2012 Present Dr. Louis G. & Mary Beth Pawelek Endowed Chair in Pediatric Rheumatology, Texas Children’s Hospital

2011 Sir William Osler Young Investigator Award - Interurban Clinical Club

2011 Philadelphia Magazine “Top Docs” – Pediatric Immunology

2011 Suburban Life “Top children’s physician”

2011 present US News and World Report “Top Doctors List”

2010 American Society of Clinical Investigation - Elected Member

2010 – 2012 Jeffrey Modell Endowed Chair in Immunology (Children's Hospital of Philadelphia)

America's Top Doctor
NY Top Doctor

Research

Grants

1. “Directing function at the natural killer cell secretory immunological synapse”, NIH NIAID R01AI067946-10; 8/07-4/20 (J. Orange Principal Investigator); Annual direct cost, $260,316 (Annual total cost 408,3066).

2. “Genetic, Immunologic and Mechanistic Basis of Human NK Cell Deficiency” NIH R01AI120989-02 1/19/16-12/31/20 (J. Orange Principal Investigator). Annual total cost 62,219

3. Diversity supplement to: “Genetic, Immunologic and Mechanistic Basis of Human NK Cell Deficiency” NIH 3R01AI120989-02W1 7/1/17-6/30/20 (J. Orange Principal Investigator). Annual direct cost 456,995. (Annual total cost 726,302)

4. “Targeting of Cellular Stress Points and Immune Priming to Relive Symptoms Associated with COPA Syndrome” Arthritis Foundation Delivering on Discovery Grant. 12/1/16-11/30/19 (J. Orange Principal Investigator). Annual Direct Cost 135,000 (overall direct cost 405,000)

5. “Understanding the biological function of MCM10”, NIH R01GM074917-10 A. Bielinsky PI (J. Orange Co-Investigator) 9/1/16-8/31/21 Annual direct cost $316,560

6. “BCM clinical site for an undiagnosed diseases network (UDN)” NHGRI-OID, 1U01HG007709-01; 7/1/14-3/30/18 (J. Orange – Pediatrics Lead); Annual direct cost $800,000 (overall direct cost 4,000,000).

7. “Immunology Scientist Training Program” NIH-NIAID T32-AI053831-11A1 (J. Orange, Steering Committee and Key Personnel) 8/4/14-8/3/19; Annual Total cost $396,680

8. Adoptive Immunotherapy for Leukemia Using Cord Blood-Derived Natural Killer Cells” American Cancer Society, K. RSG-15-218-01-LIB (Rezvani, PI, J. Orange Co-Investigator), 7/1/15-6/30/19 (overall direct cost $330,000)

Selected Publications

1. Vargas-Hernandez, A, Mace, EM, Zimmerman, O, Zerbe, CS, Freeman, AF, Rosenzweig, S, Leiding, JW, Torgerson, T, Altman, MC, Schussler, E, Cunningham-Rundles, C., Chinn, IK, Hanson, IC< Rider, NL, Holland, SM, Orange, JS, Forbes, LR. Ruxolitinib partially reverses functional NK cell deficiency in patients with STAT1 gain-of-function mutations 2017 J. Allergy Clin. Immunol. PMID: 2911217

2. Mamonkin, M, Mukherjee, M, Srinivasan, M, Sharma, S, Gomes-Silva, D, Mo, F, Krenciute, G, Orange, JS, Brenner, MK. Reversible transgene expression reduces fratricide and permits 4-1BB costimulation of CAR T cells directed to T cell malignancies. 2017 Cancer Immunol. Res. PMID: 29076555

3. Nishimura, CD, Brenner, DA, Mukherjee, M, Hirsch, RA, Ott, L, Wu, MF, Liu, H, Dakhova, O, Orange, JS, Brenner, MK, Lin, CY, Arber, C. C-MPL provides tumor-targeted T cell receptor transgenic T cells with co-stimulation and cytokine signals. 2017 Blood PMID: 29054706

4.Gomes-Silva, D, Mukherjee, M, Srinivasan, M, Krenciute, G, Dakhova, O, Zheng, Y, Cabral, JMS, Rooney, CM, Orange, JS, Brenner, MK, Mamonkin, M. Tonic 4-1BB costimulation in chimeric antigen receptors impedes T cell survival and is vector-dependent. 2017 Cell Rep. 21:17-26 PMID: 28978471

5. Bielamowicz, K, Fousek, K, Byrd, TT, Samaha, H, Mukherjee, M, Aware, N, Wu M-F, Orange, JS, Sumazin, P, Man, T-K, Joseph, SK, Hedge, M, Ahmed, N. Trivalent CAR T-cells overcome interpatient antigenic variability in glioblastoma. 2017 Neuro-Oncology PMID: 29016929